UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?

Biogen (NASDAQ:BIIB) picked up a beardown endorsement from Wall Street connected Wednesday, arsenic UBS expert Michael Yee upgraded the banal to Buy from Neutral and raised his terms people to $225 from $185. The telephone centers connected a circumstantial series of pipeline readouts Yee believes tin determination the banal meaningfully higher heading into 2027. This follows Monday's Wells Fargo upgrade, signaling that Wall Street is progressively constructive connected Biogen's near-term story.

Biogen shares traded astatine $192 Wednesday morning, up 3% connected the day. The banal has gained 62% implicit the past year, yet UBS argues it remains an "under-owned out-of-favor banal that trades astatine a discount to large-cap peers" with a compelling catalyst runway ahead.

UBS has accrued condemnation connected Biogen's pipeline based connected a concentrated model of catalysts arriving implicit the adjacent 12 to 15 months. Yee specifically points to BIIB080 tau information expected this summertime arsenic a near-term upside driver, followed by the "real upside catalyst": Phase 3 litifilimab information successful systemic lupus expected successful Q4 2026. Litifilimab already holds FDA Breakthrough Therapy Designation for cutaneous lupus, adding regulatory credibility to the program.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

The FDA granted Priority Review for LEQEMBI IQLIK, a subcutaneous formulation, with a PDUFA day of May 24. Approval would amended diligent convenience and perchance accelerate uptake of Biogen's Alzheimer's franchise, which posted $134 cardinal successful planetary in-market income successful Q4 2025, up 54% twelvemonth implicit year.

Biogen is simply a Cambridge, Massachusetts-based biopharma institution focused connected neurological and uncommon diseases. Its bequest aggregate sclerosis franchise generated $917 cardinal successful Q4 2025 revenue, down 14% twelvemonth implicit year, putting unit connected full revenue. Growth products, including LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, combined for $1 cardinal successful gross for afloat twelvemonth 2025, up 19% for the year. Biogen ended Q4 with $3.009 cardinal successful currency and generated $2.051 cardinal successful escaped currency travel for the afloat year.